Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83878 | 0.70 | — | — | |
| Hydrogen Sulfide SCHEMBL9272629 | 0.69 | TSHR (0.50) | TSHRNPSR1KDM4ELMNACYP2C19 | |
| Hydrochloric Acid SCHEMBL5728953 | 0.69 | TSHR (0.50) | TSHRNPSR1KDM4ELMNACYP2C19 | |
| SCHEMBL10456597 | 0.67 | — | — | |
| SCHEMBL10028354 | 0.67 | — | — | |
| SCHEMBL10025159 | 0.67 | — | — | |
| SCHEMBL1352364 | 0.64 | KDM4E (0.55) | TSHRNPSR1KDM4ELMNACYP2C19 | |
| SCHEMBL9471261 | 0.64 | KDM4E (0.55) | TSHRNPSR1KDM4ELMNACYP2C19 | |
| SCHEMBL13805603 | 0.64 | TSHR (0.44) | TSHRNPSR1KDM4ELMNACYP2C19 | |
| SCHEMBL23423259 | 0.63 | TSHR (0.45) | TSHRNPSR1KDM4ELMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286980-A1 | OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286980-A1 | OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND | REN, GPR119, RANBP1 | TSHR 2500/4885NPSR1 1374/4885KDM4E 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.